- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03781232
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
Non-invasive Glucose Measurement With Raman Technology. Calibration of Newly Developed Devices in Patients With Type 1 and Type 2 Diabetes - Glucobrunn Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects are recruited at two different sites.
Site 1: In group 1 subjects will on their regular stay in the clinic perform four measurement sessions a day. A measurement session consist of a reference capillary blood sample and two measures on the IMD.
Site 2: The study in group 2 consists of 26 home-based measurements and two in-clinic days. During the home measurements, 6 measurement sessions will be performed by the subjects a day. A measurement session consists of two reference BGMs, two reference CGMs and two measurements on the device. On in-clinic visits, subjects will be administered high glucose breakfast and the following 6-7 hours, measurement sessions are performed every 15 minutes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bad Heilbrunn, Germany, 83670
- m&i-Fachklinik Bad Heilbrunn - Zentrum für Diabetes und Stoffwechselerkrankungen
-
Ulm, Germany, 89081
- Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age
- Have a diagnosis of type 1 or type 2 diabetes mellitus (for RSP-09-02, only patients with type 1 diabetes)
- Skin phototype 1-4
- Be willing to perform a minimum of 6 / 12 (31 during excursion days) finger sticks per day during the study
- Be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol
- Be willing to provide written signed and dated informed consent
Exclusion Criteria:
- Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator, due to e.g. known psychiatric diagnoses, lack of cognitive ability, alcohol dependency, drug use, psychosocial overload
- Have known severe allergy to medical grade adhesive or isopropyl alcohol used to clean the skin
- Be breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control during the study execution (applicable to female subjects only)
- Unable to hold hand/arm steadily (including tremors and Parkinson's Disease)
- Severe diabetes related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s)
- Systemic or topical administration of glucocorticoids for the past 7 days
- Undergoing dialysis treatment
- Have extensive skin changes/diseases at the proposed measurement site (thenar) that could interfere with the accuracy of interstitial glucose measurements
- Have a concomitant medical condition which could interfere with the study devices (study arm 1: intake of acetaminophen study arm 2: intake of salicylic acid or higher doses of ascorbic acid)
- Unsuitable for participation due to any other cause as determined by the Investigator. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation e.g. with required documentation
- Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families)
Additional exclusion criteria for study arm 2:
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
- Hypoglycemia unawareness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RSP-09-01
Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic.
A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
Experimental: RSP-09-02
Enrolled subjects will measure at home for 26 six days and visit the clinic two times.
During home measurements, 6 measurement sessions will be performed by the subject a day.
A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3.
On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generation and validation of predictive models by Inter Subject Unified Performance (ISUP).
Time Frame: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the ISUP measure. |
2 years
|
Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures
Time Frame: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the MARD measure. |
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guido Freckmann, Dr., Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RSP-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabete Mellitus
-
Rio Grande do Sul State Health Department - SES/RSAgnes Nogueira Gossenheimer; Ana Paula Rigo; Roberto Eduardo SchneidersNot yet recruitingTelemedicine | Diabete Mellitus | Diabete Type 2 | TelehealthBrazil
-
Hospices Civils de LyonCompletedDiabete Type 2 | Diabete Type 1France
-
Abbott Diabetes CareRecruiting
-
Abbott Diabetes CareCompleted
-
Rigshospitalet, DenmarkUniversity of Southern DenmarkUnknown
-
King Khalid UniversityUnknown
-
Abbott Diabetes CareCompleted
-
Kansaa A.IbrahimCompleted
-
Medanta, The Medicity, IndiaRecruitingDiabete Mellitus | Liver Transplant; ComplicationsIndia
Clinical Trials on Prototype 0.3
-
Sheffield Children's NHS Foundation TrustCompletedRheumatologic DiseaseUnited Kingdom
-
Cryonove PharmaCEISO; DermatechCompletedPost-inflammatory HyperpigmentationSouth Africa
-
Shiphrah Biomedical Inc.University of South AustraliaTerminatedPregnancy Complications | Fetal Growth Retardation | Sleep-Disordered Breathing | Infant, Very Low Birth Weight | Stillbirth | Infant, Small for Gestational Age | Fetal Hypoxia | Infant, Low Birth WeightAustralia
-
Cryonove PharmaCEISO; Dermatech; INNOVSOLUTIONCompleted
-
Philips Electronics Nederland B.V. acting through...Leiden University Medical CenterTerminated
-
Johnson & Johnson Vision Care, Inc.Completed
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
University College, LondonUniversity of California, Santa Cruz; Anna Freud National Centre for Children... and other collaboratorsUnknown
-
Klein Buendel, Inc.National Institute on Aging (NIA); Penn State UniversityCompletedAging ProblemsUnited States
-
KalVista Pharmaceuticals, Ltd.Completed